Upgrade
| ShowHide Related Items >><< - 06/10/22 Morgan Stanley
- Lamar downgraded to Equal Weight on recession risk at Morgan Stanley
- 06/10/22 Morgan Stanley
- Lamar Advertising downgraded to Equal Weight from Overweight at Morgan Stanley
- 03/29/22 Wolfe Research
- Lamar Advertising initiated with a Peer Perform at Wolfe Research
- 07/19/21 Morgan Stanley
- Morgan Stanley equity strategist upgrades Consumer Staples, downgrades Materials
- 05/05/22
- Lamar Advertising raises FY22 AFFO view to $7.20-$7.35 from $7.03-$7.18
- 05/05/22
- Lamar Advertising reports Q1 EPS 91c, consensus 72c
- 02/25/22
- Lamar Advertising sees FY22 AFFO $7.03-$7.18
- 02/25/22
- Lamar Advertising reports Q4 EPS $1.21, consensus $1.18
- 06/10/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 03/29/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
Upgrade
| ShowHide Related Items >><< - 06/30/22
- Light & Wonder enters into amended purchase pact for sale of OpenBet to Endeavor
- 05/13/22
- Endeavor Group rises 22.0%
- 05/13/22
- Endeavor Group rises 21.3%
- 02/14/22
- Third Point buys Rivian, exits Meta in Q4
- 07/01/22 Barclays
- Endeavor Group price target raised to $28 from $27 at Barclays
- 06/23/22 Credit Suisse
- Endeavor Group assumed with an Outperform at Credit Suisse
- 06/15/22 Morgan Stanley
- Morgan Stanley upgrades Liberty Formula One, names Endeavor top pick
- 05/17/22 Goldman Sachs
- Endeavor Group upgraded to Buy from Neutral at Goldman Sachs
- 05/12/22
- Endeavor Group raises FY22 revenue view to $5.235B-$5.475B from $5.2B-$5.45B
- 05/12/22
- Endeavor Group reports Q1 EPS $1.16, consensus 42c
- 03/16/22
- Endeavor sees FY22 revenue $5.2B-$5.45B, consensus $5.11B
- 03/16/22
- Endeavor reports Q4 EPS (7c), consensus 17c
- 04/07/22
- Formula 1, WWE could be acquisition targets for streaming companies, CNBC says
- 05/13/22
- What You Missed On Wall Street On Friday
- 05/13/22
- What You Missed On Wall Street This Morning
- 05/13/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 05/12/22
- Fly Intel: After-Hours Movers
|
Periodicals
| ShowHide Related Items >><< - 07/02/22
- Seagen says Tukysa combo shows clinically meaningful antitumor activity in trial
- 06/28/22
- G1 Therapeutics announces addition of Lee to board of directors
- 06/27/22
- AstraZeneca, Merck announce LYNPARZA receives positive opinion from CHMP
- 06/27/22
- AstraZeneca's Lynparza recommended for E.U. approval by CHMP in breast cancer
- 07/03/22
- Seagen announces results from pivotal MOUNTAINEER trial
- 07/02/22
- Seagen says Tukysa combo shows clinically meaningful antitumor activity in trial
- 06/17/22
- Seattle Genetics trading resumes
- 06/17/22
- Seagen jumps 10% to $161.79 after WSJ report of Merck interest
- 05:10 Today Daiwa
- Merck upgraded to Outperform from Neutral at Daiwa (yesterday)
- 07/06/22 Daiwa
- Merck upgraded to Buy from Neutral at Daiwa
- 06/29/22 Raymond James
- Seagen initiated with an Outperform at Raymond James
- 06/28/22 Piper Sandler
- Sutro Biopharma price target raised to $16 from $14 at Piper Sandler
- 06/29/22 Raymond James
- Seagen initiated with an Outperform at Raymond James
- 06/28/22 Piper Sandler
- Sutro Biopharma price target raised to $16 from $14 at Piper Sandler
- 06/27/22 Cowen
- Merck price target raised to $102 from $95 at Cowen
- 06/24/22 Mizuho
- Merck deal would add 'novel and validated technology,' says Mizuho
- 04/28/22
- Merck raises FY22 adjusted EPS view to $7.24-$7.36, consensus $7.24
- 04/28/22
- Merck reports Q1 adjusted EPS $2.14, consensus $1.83
- 04/27/22
- Notable companies reporting before tomorrow's open
- 04/27/22
- Notable companies reporting before tomorrow's open
- 04/28/22
- Seagen sees FY22 total revenue $1.665B-$1.745B, consensus $1.78B
- 04/28/22
- Seagen reports Q1 EPS (74c), consensus ($1.00)
- 02/10/22
- Seagen sees FY22 total revenue $1.67B-$1.75B, consensus $2.16B
- 02/09/22
- Seagen reports Q4 EPS (95c), consensus (83c)
- 06/24/22
- Merck moving forward with potential Seagen deal, WSJ reports
- 06/17/22
- Merck, other suitors interested in acquiring Seagen, WSJ reports
- 06/17/22
- Merck considering acquisition of Seagen, WSJ reports
- 05/31/22
- Pfizer's Paxlovid becomes leading pandemic pill, WSJ reports
- 06/24/22
- Merck moving forward with potential Seagen deal, WSJ reports
- 06/17/22
- Merck, other suitors interested in acquiring Seagen, WSJ reports
- 06/17/22
- Merck considering acquisition of Seagen, WSJ reports
- 06/24/22
- What You Missed On Wall Street On Friday
- 06/24/22
- What You Missed On Wall Street This Morning
- 06/24/22
- Fly Intel: Pre-market Movers
- 06/17/22
- What You Missed On Wall Street On Friday
- 06/24/22
- What You Missed On Wall Street On Friday
- 06/24/22
- What You Missed On Wall Street This Morning
- 06/24/22
- Fly Intel: Pre-market Movers
- 06/17/22
- What You Missed On Wall Street On Friday
- 07/06/22
- Unusually active option classes on open July 6th
- 06/01/22
- Merck put volume heavy and directionally bearish
- 05/31/22
- Merck put volume heavy and directionally bearish
- 05/18/22
- Merck put volume heavy and directionally bearish
|
Periodicals
|
Tom Keane, a Microsoft VP… ShowHide Related Items >><< - 07/06/22
- U.K. opens competition investigation into Microsoft, Activision deal
- 07/05/22
- EU regulators adopt new rules to monitor 'Tech Giants'
- 07/01/22
- CWA supports Microsoft's proposed Activision Blizzard takeover in FTC letter
- 06/30/22
- Samsung launches Gaming Hub for Samsung Smart TVs
- 07/06/22 Needham
- RingCentral downgraded to Hold from Buy at Needham
- 06/29/22 Redburn
- Microsoft initiated with a Buy at Redburn
- 06/27/22 William Blair
- Okta not seeing backlash from security breach, says William Blair
- 06/24/22 Citi
- Citi names top software picks with sector de-rating 'mostly done'
- 06/02/22
- Microsoft lowers Q4 EPS view to $2.24-$2.32 from $2.28-$2.35, consensus $2.33
- 04/26/22
- Microsoft sees Q4 productivity and business processes revenue $16.65B-$16.9B
- 04/26/22
- Microsoft reports Q3 EPS $2.22 consensus $2.18
- 04/26/22
- Notable companies reporting after market close
- 07/06/22
- Nintendo Switch sales rise 24% y/y in U.K. in June, Gamesindustry.biz says
- 07/05/22
- Amazon,Microsoft, Google keep firm grip on cloud computing space, WSJ says
- 07/02/22
- Activision stock is a bet worth making on Microsoft's takeover, Barron's says
- 07/01/22
- Microsoft's Azure suffering from limited server capacity, Information reports
- 07/06/22
- What You Missed On Wall Street On Wednesday
- 07/06/22
- What You Missed On Wall Street This Morning
- 07/06/22
- What You Missed This Week in Video Games
- 07/06/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 06/03/22
- Unusually active option classes on open June 3rd
- 06/02/22
- Unusually active option classes on open June 2nd
- 05/31/22
- Microsoft call volume above normal and directionally bullish
- 05/02/22
- Microsoft put buyer realizes 57% same-day gains
|
Upgrade
|
BTIG analyst David Larsen… BTIG analyst David Larsen upgraded 1Life Healthcare (ONEM) to Buy from Neutral with a $15 price target. Over the past two years, the stock has traded down from $60 to $10, making the multiple "far more reasonable now than it has been in the past," Larsen tells investors in a research note. The analyst also believes that the odds of 1Life being acquired are "fairly high." While the stock rallied 25% on July 5 following a Bloomberg article discussing a possible takeout, 1Life has further valuation upside potential driven by improving Medicare margins, steady membership and revenue growth, cross-sales between Medicare and Commercial, an abatement of COVID, and "well-managed" expectations, contends Larsen. He believes potential acquirers of the business include CVS Health (CVS), a large health plan such as UnitedHealth Group (UNH) or Elevance Health (ELV), or possibly a large publicly traded hospital system. A strategic takeout "seems a very real possibility," writes Larsen. ShowHide Related Items >><< - 07/05/22
- 1Life Healthcare up 14% to $9.46 after Bloomberg report of takeover interest
- 07/05/22
- 1Life Healthcare trading resumes
- 07/05/22
- 1Life Healthcare trading halted, volatility trading pause
- 02/24/22
- 1Life Healthcare trading resumes
- 06/30/22
- CVS Health exec sells $13.2M in common stock
- 06/07/22
- FTC announces inquiry into pharmacy benefit managers
- 05/09/22
- Aris Water Solutions reaches water management pact with Chevron
- 05/04/22
- CVS Health reports 98% core client retention for 2023 selling season
- $515.28 /
+10.54 (+2.09%) - 06/17/22
- UnitedHealth subsidiary to acquire EMIS Group in deal valued at GBP 1.24B
- 06/10/22
- LHC Group, UnitedHealth receive second request for information from FTC
- 06/08/22
- UnitedHealth announces quarterly dividend of $1.65 per share
- 06/07/22
- FTC announces inquiry into pharmacy benefit managers
- $484.65 /
+8.295 (+1.74%) - 06/28/22
- Anthem begins trading under new name 'Elevance Health,' ticker symbol 'ELV'
- 07/06/22 Deutsche Bank
- 1Life would not check 'earnings box' for CVS, says Deutsche Bank
- 07/06/22 Citi
- Citi not seeing 'wide buyer universe' for 1Life outside of CVS
- 07/05/22 Stifel
- Stifel says 'logical to assume' Walgreens could look at 1Life Healthcare
- 06/16/22 Deutsche Bank
- 1Life Healthcare market cap now below last private raise, says Deutsche Bank
- 07/06/22 Deutsche Bank
- 1Life would not check 'earnings box' for CVS, says Deutsche Bank
- 07/06/22 Citi
- Citi not seeing 'wide buyer universe' for 1Life outside of CVS
- 07/05/22 Stifel
- Stifel says 'logical to assume' Walgreens could look at 1Life Healthcare
- 06/16/22 Loop Capital
- Loop Capital starts CVS Health at Buy citing position to capitalize on Medicare
- $515.28 /
+10.54 (+2.09%) - 07/05/22 Stifel
- Stifel says 'logical to assume' Walgreens could look at 1Life Healthcare
- 06/16/22 Loop Capital
- Loop starts UnitedHealth at Buy, sees company having 'major' advantages
- 06/16/22 Loop Capital
- UnitedHealth initiated with a Buy at Loop Capital
- 06/01/22 Citi
- Change Healthcare price target raised to $27.75 from $25.75 at Citi
- $484.65 /
+8.295 (+1.74%) - 05/04/22
- 1Life Healthcare sees FY22 revenue $1.055B-$1.095B, consensus $1.07B
- 05/04/22
- 1Life Healthcare sees Q2 revenue $255M-$270M, consensus $263.36M
- 05/04/22
- 1Life Healthcare reports Q1 EPS (47c), consensus (49c)
- 02/23/22
- 1Life Healthcare sees FY22 revenue $1.05B-$1.09B, consensus $1.07B
- 06/09/22
- CVS Health reaffirms FY22 adjusted EPS view $8.20-$8.40, consensus $8.36
- 05/04/22
- CVS Health raises FY22 Health Care benefits revenue view to $89.3B-$90.8B
- 05/04/22
- CVS Health raises FY22 revenue view to $305B-$310B from $304B-$309B
- 05/04/22
- CVS Health raises FY22 adjusted EPS view to $8.20-$8.40 from $8.10-$8.30
- $515.28 /
+10.54 (+2.09%) - 04/14/22
- UnitedHealth raises FY22 adjusted EPS view to $21.20-$21.70 from $21.10-$21.60
- 04/14/22
- UnitedHealth reports Q1 adjusted EPS $5.49, consensus $5.38
- 04/13/22
- Notable companies reporting before tomorrow's open
- 04/13/22
- Notable companies reporting before tomorrow's open
- 07/05/22
- 1Life Healthcare weighs options after drawing takeover interest, Bloomberg says
- 07/05/22
- 1Life Healthcare weighs options after drawing takeover interest, Bloomberg says
- 03/08/22
- Lawmakers considering extending telehealth policies, STATNews reports
- 07/05/22
- 1Life Healthcare weighs options after drawing takeover interest, Bloomberg says
- 07/05/22
- 1Life Healthcare weighs options after drawing takeover interest, Bloomberg says
- 06/27/22
- CVS, Walmart rationing Plan B pills amid demand surge, WSJ reports
- 05/25/22
- CVS to stop filling controlled substance prescriptions for Cerebral, WSJ reports
- $515.28 /
+10.54 (+2.09%) - 05/20/22
- UnitedHealth focuses on telehealth to reduce costs, WSJ reports
- 04/04/22
- Change Healthcare in talks to sell ClaimsXten business, Bloomberg says
- 03/24/22
- UnitedHealth's Optum bought Refresh Mental Health from PE owner, Axios reports
- 02/24/22
- UnitedHealth plans to challenge DOJ's lawsuit, Reuters reports
- 07/05/22
- What You Missed On Wall Street On Tuesday
- 05/04/22
- Fly Intel: After-Hours Movers
- 02/23/22
- Fly Intel: After-Hours Movers
- 06/17/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 06/09/22
- What You Missed On Wall Street On Thursday
- 06/09/22
- What You Missed On Wall Street This Morning
- 06/07/22
- What You Missed On Wall Street On Tuesday
- $515.28 /
+10.54 (+2.09%) - 06/07/22
- What You Missed On Wall Street On Tuesday
- 05/27/22
- What You Missed On Wall Street On Friday
- 05/27/22
- What You Missed On Wall Street This Morning
- 05/27/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 05/04/22
- 1Life Healthcare options imply 17.3% move in share price post-earnings
- 02/23/22
- 1Life Healthcare options imply 18.1% move in share price post-earnings
- 06/02/22
- CVS Health put volume heavy and directionally bearish
- 05/04/22
- Unusually active option classes on open May 4th
- 05/02/22
- Unusually active option classes on open May 2nd
- 04/26/22
- CVS Health call volume above normal and directionally bullish
- $515.28 /
+10.54 (+2.09%) - 07/05/22
- UnitedHealth put volume heavy and directionally bearish
- 06/22/22
- Unusually active option classes on open June 22nd
- 06/09/22
- UnitedHealth put volume heavy and directionally bearish
- 03/14/22
- UnitedHealth put volume heavy and directionally bearish
|
Periodicals
|
Shell (SHEL) is investing… ShowHide Related Items >><< - 07/05/22
- Shell selected by QatarEnergy as partner in North Field East expansion project
- 07/05/22
- Shell, AMG Recycling, Aramco enter agreement for supercenter complex
- 06/29/22
- Equinor sells 51% interest in North Platte project to Shell
- 06/27/22
- Wolf Capital issues open letter on Shell's offer for Shell Midstream Partners
- 07/05/22
- TechnipFMC awarded iFEED contract by Equinor
- 06/30/22
- Equinor announces completed share capital reduction
- 06/29/22
- Equinor sells 51% interest in North Platte project to Shell
- 06/09/22
- Cheniere Energy, Equinor sign long-term LNG sale, purchase agreement
- 07/06/22 Deutsche Bank
- Shell price target raised to 2,779 GBp from 2,551 GBp at Deutsche Bank
- 06/09/22 Credit Suisse
- Shell initiated with an Outperform at Credit Suisse
- 05/11/22 Morgan Stanley
- Shell price target raised to 2,860 GBp from 2,570 GBp at Morgan Stanley
- 05/06/22 UBS
- Shell price target raised to 2,550 GBp from 2,450 GBp at UBS
- 07/06/22 Deutsche Bank
- Equinor price target raised to NOK 354 from NOK 314 at Deutsche Bank
- 06/17/22 JPMorgan
- Equinor upgraded to Neutral from Underweight at JPMorgan
- 06/09/22 Credit Suisse
- Equinor initiated with a Neutral at Credit Suisse
- 05/20/22 Societe Generale
- Equinor downgraded to Hold from Buy at Societe Generale
- 05/05/22
- Shell reports Q1 adjusted EPS $1.20 vs. 42c last year
- 07/06/22
- OPEC Secretary-General Mohammad Barkindo dies, Bloomberg reports
- 06/15/22
- Biden calls on oil refiners to boost supply of gas, diesel, CNBC reports
- 06/14/22
- Finance chair to propose surtax on excessive oil company profits, Bloomberg says
- 06/11/22
- Sunrun, Shell among energy stocks to consider, Barron's says
- 03/12/22
- Equinor 'the stock to play' European gas, Barron's says
- 03/10/22
- Equinor ceases trading Russian oil, Reuters reports
- 06/15/22
- What You Missed On Wall Street On Wednesday
- 06/09/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 06/08/22
- What You Missed On Wall Street On Wednesday
- 05/31/22
- What You Missed On Wall Street On Tuesday
- 06/07/22
- What You Missed On Wall Street On Tuesday
- 06/07/22
- What You Missed On Wall Street This Morning
- 07/05/22
- Unusually active option classes on open July 5th
- 06/29/22
- Shell PLC put volume heavy and directionally bearish
- 06/16/22
- Shell PLC put volume heavy and directionally bearish
- 06/13/22
- Shell PLC call volume above normal and directionally bullish
- 05/16/22
- Largest borrow rate increases among liquid names
- 05/12/22
- Largest borrow rate increases among liquid names
|
Initiation
| ShowHide Related Items >><< - 06/21/22
- EyePoint announce approval of new drug application by China's NMPA for YUTIQ
- 06/16/22
- EyePoint reports inducement grants under Nasdaq listing rule
- 06/10/22
- EyePoint to present 12-month results from Phase 1 DAVIO trial
- 05/16/22
- EyePoint reports inducement grants under Nasdaq listing rule
- 11/16/21 Cantor Fitzgerald
- EyePoint stock movement unwarranted, says Cantor Fitzgerald
- 11/15/21 Cowen
- EyePoint price target raised to $35 from $25 at Cowen
- 11/15/21 Cowen
- EyePoint price target raised to $35 from $25 at Cowen
- 11/15/21 Guggenheim
- EyePoint price target raised to $75 from $22 at Guggenheim
- 05/04/22
- EyePoint reports Q1 EPS (56c), consensus (58c)
- 03/03/22
- EyePoint expects cash expects cash to fund operations through H2 of 2024
- 03/03/22
- EyePoint reports Q4 EPS (59c), consensus (53c)
|
Upgrade
|
Investec analyst Herbert… ShowHide Related Items >><< - 06/06/22
- AngloGold, Latin Metals enter definitive option agreement in Argentina
- 02/23/22
- AngloGold announces 3.37M ounce gold resource on Orogen's royalty interest
- 02/14/22
- Paulson buys Cerner, exits Pretium in Q4
- 01/18/22
- Corvus Gold, AngloGold Ashanti complete acquisition
- 06/29/22 Deutsche Bank
- AngloGold Ashanti price target lowered to $21 from $25 at Deutsche Bank
- 03/10/22 Deutsche Bank
- AngloGold Ashanti price target raised to $28 from $24 at Deutsche Bank
- 03/07/22 JPMorgan
- AngloGold Ashanti upgraded to Overweight from Neutral at JPMorgan
- 03/01/22 Investec
- AngloGold Ashanti upgraded to Hold from Sell at Investec
|
Downgrade
|
Investec analyst Nkateko… ShowHide Related Items >><< - 07/05/22 JPMorgan
- Anglo American price target raised to 3,800 GBp from 3,350 GBp at JPMorgan
- 06/29/22 Deutsche Bank
- Anglo American downgraded to Hold from Buy at Deutsche Bank
- 06/23/22 Morgan Stanley
- Anglo American price target lowered to 3,400 GBp at Morgan Stanley
- 06/22/22 JPMorgan
- Anglo American price target lowered to 3,350 GBp from 3,450 GBp at JPMorgan
|
Downgrade
|
Investec analyst Nkateko… ShowHide Related Items >><< - 03/08/22
- Sibanye Stillwater falls -9.8%
- 06/29/22 Deutsche Bank
- Sibanye Stillwater price target lowered to $14 from $17 at Deutsche Bank
- 06/01/22 RBC Capital
- RBC Capital cuts Sibanye Stillwater to Sector Perform on challenging environment
- 06/01/22 RBC Capital
- Sibanye Stillwater downgraded to Sector Perform from Outperform at RBC Capital
- 05/09/22 Goldman Sachs
- Sibanye Stillwater initiated with a Buy at Goldman Sachs
- 05/31/22
- Sibanye Stillwater call volume above normal and directionally bullish
- 05/09/22
- Sibanye Stillwater put volume heavy and directionally bearish
- 04/08/22
- Unusually active option classes on open April 8th
- 03/28/22
- Largest borrow rate increases among liquid names
|